anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A standardisable protein-free extract, which promotes vesicular respiration and RES activity, is produced from haemolysed blood or corresp. treated marrow or parts of the organs of mammals by (a) adjusting the haemolysate to a weakly acidic pH by adding a soln. of an acid, present in the organism, or its salt; (b) heating the stirred mixt. on a water bath (pref. at 50-95 degrees C for 5-30 min.); (c) filtering and centrifuging to remove proteins and enzymes; and (d) evaporating to dryness in vacuo. The acid is pref. lactic, ascorbic or or acetic acid.
Sodium Bicarbonate Injection, USP is administered by the intravenous route.

In cardiac arrest, a rapid intravenous dose of one to two 50 mL vials (44.6 to 100 mEq) may be given initially and continued at a rate of 50 mL (44.6 to 50 mEq) every 5 to 10 minutes if necessary (as indicated by arterial pH and blood gas monitoring) to reverse the acidosis. Caution should be observed in emergencies where very rapid infusion of large quantities of bicarbonate is indicated. Bicarbonate solutions are hypertonic and may produce an undesirable rise in plasma sodium concentration in the process of correcting the metabolic acidosis. In cardiac arrest, however, the risks from acidosis exceed those of hypernatremia.

In less urgent forms of metabolic acidosis, Sodium Bicarbonate Injection, USP may be added to other intravenous fluids. The amount of bicarbonate to be given to older children and adults over a four-to-eight-hour period is approximately 2 to 5 mEq/kg of body weight – depending upon the severity of the acidosis as judged by the lowering of total CO2 content, blood pH and clinical condition of the patient. In metabolic acidosis associated with shock, therapy should be monitored by measuring blood gases, plasma osmolarity, arterial blood lactate, hemodynamics and cardiac rhythm. Bicarbonate therapy should always be planned in a stepwise fashion since the degree of response from a given dose is not precisely predictable. Initially an infusion of 2 to 5 mEq/kg body weight over a period of 4 to 8 hours will produce a measurable improvement in the abnormal acid-base status of the blood. The next step of therapy is dependent upon the clinical response of the patient. If severe symptoms have abated, then the frequency of administration and the size of the dose may be reduced.

In general, it is unwise to attempt full correction of a low total CO2 content during the first 24 hours of therapy, since this may be accompanied by an unrecognized alkalosis because of a delay in the readjustment of ventilation to normal. Owing to this lag, the achievement of total CO2 content of about 20 mEq/liter at the end of the first day of therapy will usually be associated with a normal blood pH. Further modification of the acidosis to completely normal values usually occurs in the presence of normal kidney function when and if the cause of the acidosis can be controlled. Values for total CO2 which are brought to normal or above normal within the first day of therapy are very likely to be associated with grossly alkaline values for blood pH, with ensuing undesired side effects.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit (See PRECAUTIONS).
OBJECTIVE: Evidence for an association between locomotive syndrome (LS) and depression is lacking in middle-aged women. This study aimed to investigate the relationship between LS severity and depressive symptoms in community-dwelling middle-aged women.
METHODS: This cross-sectional study included 1520 middle-aged women (mean age 52 ± 6 years). LS severity was evaluated using the 25-question Geriatric Locomotive Function Scale questionnaire and motor function test. Depressive symptoms were assessed using the Zung self-rating depression scale. Multiple logistic regression analyses were performed to determine the association between depressive symptoms and LS severity, adjusting for potential confounding factors.
RESULTS: LS severity, as evaluated through both questionnaires and motor function tests, was significantly associated with depressive symptoms (self-rating depression scale  ≥ 40 points) in middle-aged women. The relationship between LS and depressive symptoms was only significant when assessed through the 25-question Geriatric Locomotive Function Scale questionnaire rather than the motor function tests. Additionally, a stepwise association was observed between pain severity, as assessed by the 25-question Geriatric Locomotive Function Scale, and the prevalence of depressive symptoms.
CONCLUSIONS: LS severity is significantly associated with depressive symptoms in community-dwelling middle-aged women, suggesting the need for additional mental status assessment in participants with LS and concurrent pain.
Periodontal disease disrupts soft tissue metabolism in the gingiva through a decrease in the production of collagen, the quality, and quantity of the connective tissue. The etiology and pathogenesis of chronic periodontitis are mostly revealed however, there are many dark points in the etiopathogenesis of aggressive periodontitis. The existence of periodontal destruction at even one tooth in the mouth increases the risk of further periodontal destruction. However, the incidence of progression of the disease to the unaffected teeth was not demonstrated. Yet, the progression of the disease from diseased sites to healthy sites is likely to occur but no evidence is present comparing healthy and diseased sites of chronic and aggressive periodontitis. Present study aimed to evaluate the histological changes in both diseased and healthy sites in both localized aggressive periodontitis (LAgP) and chronic periodontitis (CP) patients by determining fibroblast and inflammatory cell counts in histologic slides and immunohistochemical staining of enzymes and hypoxia markers in order to better understand the dimensions of this demolition in periodontal disease.
PROBLEM TO BE SOLVED: To obtain the subject powder well dispersible in an aqueous medium and excellent in stability without aggregating even in the presence of an acrylic thickener by coating a powder with a specific core-shell type emulsion resin. SOLUTION: This powder is obtained by coating a powder with a core-shell type emulsion resin having an acrylic water-soluble polymer [preferably the polymer containing (meth)acrylic acid, an acrylic or a methacrylic ester, styrene, etc.], in the shell and a water-insoluble polymer (preferably the polymer of styrene, an α-alkylstyrene, etc.), in the inner core. The powder to be coated is preferably a powder in which the surface is pretreated with a hydrogenmethylpolylsiloxane, dimethylpolysiloxane and a silane coupling agent. The ratio of the powder to the core-shell type emulsion is preferably (95.5:0.5) to (50:50). Thereby, a powder-dispersed cosmetic excellent in stability can be obtained in the presence of an aqueous medium.
BACKGROUND: Inguinal lymph node dissection plays an important role in the management of melanoma, penile and vulval cancer. Inguinal lymph node dissection is associated with various intraoperative and postoperative complications with significant heterogeneity in classification and reporting. This lack of standardization challenges efforts to study and report inguinal lymph node dissection outcomes. The aim of this study was to devise a system to standardize the classification and reporting of inguinal lymph node dissection perioperative complications by creating a worldwide collaborative, the complications and adverse events in lymphadenectomy of the inguinal area (CALI) group.
METHODS: A modified 3-round Delphi consensus approach surveyed a worldwide group of experts in inguinal lymph node dissection for melanoma, penile and vulval cancer. The group of experts included general surgeons, urologists and oncologists (gynaecological and surgical). The survey assessed expert agreement on inguinal lymph node dissection perioperative complications. Panel interrater agreement and consistency were assessed as the overall percentage agreement and Cronbach's α.
RESULTS: Forty-seven experienced consultants were enrolled: 26 (55.3%) urologists, 11 (23.4%) surgical oncologists, 6 (12.8%) general surgeons and 4 (8.5%) gynaecology oncologists. Based on their expertise, 31 (66%), 10 (21.3%) and 22 (46.8%) of the participants treat penile cancer, vulval cancer and melanoma using inguinal lymph node dissection respectively; 89.4% (42 of 47) agreed with the definitions and inclusion as part of the inguinal lymph node dissection intraoperative complication group, while 93.6% (44 of 47) agreed that postoperative complications should be subclassified into five macrocategories. Unanimous agreement (100%, 37 of 37) was achieved with the final standardized classification system for reporting inguinal lymph node dissection complications in melanoma, vulval cancer and penile cancer.
CONCLUSION: The complications and adverse events in lymphadenectomy of the inguinal area classification system has been developed as a tool to standardize the assessment and reporting of complications during inguinal lymph node dissection for the treatment of melanoma, vulval and penile cancer.
Period 1: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.
BACKGROUND: Chronic cough after pulmonary resection is one of the most common complications, which seriously affects the quality of life of patients after surgery. Therefore, the aim of this study is to explore the risk factors of chronic cough after pulmonary resection and construct a prediction model.
METHODS: The clinical data and postoperative cough of 499 patients who underwent pneumonectomy or pulmonary resection in The First Affiliated Hospital of University of Science and Technology of China from January 2021 to June 2023 were retrospectively analyzed. The patients were randomly divided into training set (n=348) and validation set (n=151) according to the principle of 7:3 randomization. According to whether the patients in the training set had chronic cough after surgery, they were divided into cough group and non-cough group. The Mandarin Chinese version of Leicester cough questionnare (LCQ-MC) was used to assess the severity of cough and its impact on patients' quality of life before and after surgery. The visual analog scale (VAS) and the self-designed numerical rating scale (NRS) were used to evaluate the postoperative chronic cough. Univariate and multivariate Logistic regression analysis were used to analyze the independent risk factors and construct a model. Receiver operator characteristic (ROC) curve was used to evaluate the discrimination of the model, and calibration curve was used to evaluate the consistency of the model. The clinical application value of the model was evaluated by decision curve analysis (DCA).
RESULTS: Multivariate Logistic analysis screened out that preoperative forced expiratory volume in the first second/forced vital capacity (FEV1/FVC), surgical procedure, upper mediastinal lymph node dissection, subcarinal lymph node dissection, and postoperative closed thoracic drainage time were independent risk factors for postoperative chronic cough. Based on the results of multivariate analysis, a Nomogram prediction model was constructed. The area under the ROC curve was 0.954 (95%CI: 0.930-0.978), and the cut-off value corresponding to the maximum Youden index was 0.171, with a sensitivity of 94.7% and a specificity of 86.6%. With a Bootstrap sample of 1000 times, the predicted risk of chronic cough after pulmonary resection by the calibration curve was highly consistent with the actual risk. DCA showed that when the preprobability of the prediction model probability was between 0.1 and 0.9, patients showed a positive net benefit.
CONCLUSIONS: Chronic cough after pulmonary resection seriously affects the quality of life of patients. The visual presentation form of the Nomogram is helpful to accurately predict chronic cough after pulmonary resection and provide support for clinical decision-making.
The present invention provides a skin-improving composition including a material, as an active material, for inhibiting expression of at least one from cadherin 11 and N-cadherin, and a skin-improving kit including the same. According to the present invention, cutaneous hyperpigmentation can be alleviated; a skin whitening effect can be provided; and an excellent anti-aging effect can be provided as the skin-improving composition can prevent or alleviate generation of wrinkles. The present invention provides a system for screening a skin-improving material including a co-culture product of at least two from fibroblast, keratinocyte and melanocyte, and a method for screening a skin improving material. The method includes the steps of: treating the co-culture product of the system for screening a skin-improving material with candidate materials; and measuring change of expression of at least one from cadherin 11 and N-cadherin. The change of expression of at least one from cadherin 11 and N-cadherin can be clinically measured in vitro and in an easy manner. Therefore, a skin-improving material can be effectively screened.
The invention relates to a manufacturing method of water lily cough syrup. The water lily cough syrup is prepared from water lily flower, licorice root, honeysuckle flower, xylitol and honey as main raw materials by special processes. With the deterioration of the ecological environment and continuous increasing of social pressure, human immunity becomes poorer day by day and can suffer from cough because of various reasons. Water lily flower has mild properties, has a bitter and sweet taste, has effects of invigorating blood circulation and stopping bleeding, dispersing blood stasis and relieving pain, dispelling wind-evil and clearing damp, clearing heart and cooling blood, invigorating spleen and astringing intestine to stop diarrhea, and promoting the production of body fluid to quench thirst and can be used as a drug for treating cough. At present, the water lily cough syrup product is not found on the market. The water lily cough syrup combines water lily flower, licorice root, isatis root, root of large-flowered skullcap and honeysuckle flower effects of invigorating blood circulation and stopping bleeding, clearing heat and removing toxins, clearing heart and cooling blood, invigorating spleen and astringing intestine to stop diarrhea, promoting the production of body fluid to quench thirst, and relieving cough and moistening lung, and has substantial cough-relieving effects. Xylitol and honey can mask a bitter taste and has a good taste. The water lily cough syrup is suitable for patients suffering from cough caused by inflammation and endogenous fire.
Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity.
Eligible subjects will be monitored with a SEEQ device. The SEEQ device is a patch-like device that is worn externally on the chest and continuously monitors heart rhythm. Each device is worn for seven days and replaced with additional devices for a total of 28 days of monitoring. Subjects will return the SEEQ equipment at the end of the monitoring period. Subjects will be contacted by telephone or seen at the clinic approximately 60 days from the first day of monitoring. Information will be gathered about medications and any cardiac interventions the subject may have had.

Subjects will again be contacted by telephone or seen in the clinic approximately 1 year from study start. Information will be gathered about general health, changes in medications, and cardiac interventions or events. Cardiac testing results will be reviewed.
FIELD: medicine. 
     SUBSTANCE: method involves treating nasal cavity mucous membrane, paranasal sinuses and rhinopharynx and oropharynx communicating with them. Sanitization is carried out with remote ultrasonic jet aerosol spraying carried out with ozone/NO-solution containing drug. Ultrasonic oscillations frequency is equal to 26.5 kHz. Ultrasonic oscillations amplitude is equal to 60-80 mcm. Ultrasonic jet aerosol spraying exposure time is equal to 15-30 s. Ozonized physiologic saline consumption rate is not less than 10 ml/min. Ozonized 5-10% oil-in-water type oil emulsion consumption rate is not less than 5 ml/min. Ozone concentration in physiologic saline is not less than 1.2 mg/l. Ozonides concentration in ozonized 5-10% oil-in-water type oil emulsion is not less than 100 mMole of O act  per 1 kg of emulsion. Local nasal cavity and paranasal sinuses mucous membrane insonation is carried out at the second stage. Ozone/NO-containing drug is used as intermediate treatment solution. Ultrasonic oscillations frequency is equal to 26.5 kHz in this case. Ultrasonic oscillations amplitude of waveguide instrument is equal to 45-50 mcm. Insonation is carried out in intermittent with 2:1 on-off time ratio. Total ozone/NO ultrasonic treatment is not shorter than 120 s. Ultrasonic device system rarefaction degree for treating cavity is not greater than 0.3 kg/cm. Ozonized physiologic saline or ozonized 5-10% oil-in-water type oil emulsion consumption rate is not less than 60-120 ml/min. Ozone concentration in ozonized physiologic saline is not less than 1.2 mg/l. Ozonides concentration in ozonized 5-10% oil-in-water type oil emulsion is not less than 100 mMole of O act  per 1 kg of emulsion. Sanitization procedure is applied once more at the third treatment stage. 
     EFFECT: enhanced effectiveness of treatment; accelerated treatment course. 
     4 cl, 8 dwg
In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure. Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Section 5.2). 

Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent's labeling. 

Technetium Tc99m Sestamibi has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria. In some patients the allergic symptoms developed on the second injection during Tc99m Sestamibi imaging. Patients who receive Technetium Tc99m Sestamibi for either myocardial or breast imaging are receiving the same drug. Caution should be exercised and emergency equipment should be available when administering Technetium Tc99m Sestamibi. Also, before administering Technetium Tc99m Sestamibi Injection, patients should be asked about the possibility of allergic reactions to the drug.
<P>PROBLEM TO BE SOLVED: To obtain a bacterium for preventing a decayed tooth, a food for hardly decaying a tooth by eating, an oral cavity cleaning agent for preventing a decayed tooth and a method for producing yogurt hardly decaying a tooth by eating.  <P>SOLUTION: The bacterium controls growth of Mutans streptococci belonging to the genus Lactobucillus, namely the bacterium for preventing a decayed tooth belongs to the genus Lactobucillus. Especially Lactobacillus reuteri is cited as the bacterium. The food containing the bacterium prevents a decayed tooth by eating. The oral cavity cleaning agent containing the bacterium makes the oral cavity clean, controls growth of a decayed tooth causative and effectively prevents a decayed tooth. Yogurt hardly readily causing a decayed tooth is produced when produced in the presence of the bacterium.  <P>COPYRIGHT: (C)2004,JPO
Seborrheic dermatitis including seborrhea sicca \- Shake well before use. Wash affected areas twice daily (morning and evening) or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin working into a full lather, rinse thoroughly, pat dry and repeat after 10 to 20 seconds. Rinsing with plain water will remove any excess medication. Repeat application as described above for 8 to 10 days or as directed by your physician. lf skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less frequently. Regular shampooing following the use of this product is not necessary, but the hair should be shampooed at least once a week. As the condition subsides, the interval between applications may be lengthened. Applications once or twice weekly or every other week may prevent recurrence. Should the condition recur after stopping therapy, the application of this product should be reinitiated as at the beginning of treatment. 

Secondary cutaneous bacterial infections \- Shake well before use. Wash affected areas twice daily (morning and evening) or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10 to 20 seconds working into a full lather, rinse thoroughly and pat dry. Rinsing with plain water will remove any excess medication. Repeat application as described above for 8 to 10 days or as directed by your physician. If skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less frequently.
Despite significant developments in assistant reproductive technology (ART) that have overcome many underlying causes of infertility, pregnancy success rates remain relatively low, mainly due to implantation failure. Embryo quality and endometrial receptivity are two significant factors that believed to be the key points in implantation. Since recent studies that showed high expression of some HOXA genes affects on successful implantation rate, thus we examined the expression of HOXA genes in NAC supplementation during window of implantation (WOI) in women with (RIF). Also the effect of NAC on the improvement of implantation in RIF patients was investigated. Forty unfertile women with a diagnosis of RIF, referred to Royan Institute were included in the study. The study was of the type a single center, double blinded, placebo controlled, randomized trial. Expression of HOXA genes were assessed on the day of WOI (using Real Time PCR) biopsies from endometrium. Subjects randomly assigned to receive either NAC (A) or placebo (B) with both effervescent tablets having similar color, size and appearance. The patients were randomly categorized in two groups (A/B) to receive NAC 1200 mg/day or placebo, for at-least 6 weeks before starting ovarian stimulation. Pipelled-based biopsy from endometrium was done on specific day (19-21) of their cycle. Then patients were undergone ovarian stimulation (using NAC) ended to IVF treatment. RNA extraction and cDNA synthesis were performed from endometrium samples and then we evaluated expressions levels by Real-time PCR. Then we analyzed our data by independent Sample T-test and Mann-whitney U Test.
The control group will receive therapy as usual. Currently, this means that patients are immobilized during first 3-4 weeks. The control group will receive additional relaxation training during this period to achieve the same total amount of time the therapist spends with the patients of the experimental groups.
Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368. This will determine the recommended phase two dose (RP2D) of ABBV-927.